Trump touts Axon (AXON) stock ahead of federal agency expansion

Axon Enterprise (NASDAQ:AXON) makes the taser, body cameras and a widening suite of software that police departments and now federal agencies rely on, and the stock just fell 6.06% to 601.53 dollars after weeks of speculation about how much of its future growth depends on federal immigration enforcement contracts.

A Trust, a Contract Notice and a Two Week Gap

On February 10, President Trump bought between 1 million and 5 million dollars of Axon shares, per disclosures filed with the Office of Government Ethics in May. Fourteen days later, Immigration and Customs Enforcement posted a notice seeking roughly 17,800 new tasers under a proposed five year, 220 million dollar contract, plus unlimited cartridges and training. The listing does not mention Axon by name, but three policing procurement experts told reporters the specified 45 foot range and ten probe configuration match only the company's Taser 10. Axon already controls about 90% of the domestic taser market, according to Brown Advisory. The White House says the holdings sit in a trust managed by Trump's children and independent firms, and spokesperson Anna Kelly called any suggestion of conflict a tired narrative. Jordan Libowitz of Citizens for Responsibility and Ethics in Washington sees the optics differently, noting the administration's own enforcement expansion could lift a company the president holds a stake in. No award has been made on the ICE order, and nothing indicates Trump knew the request was coming or that ICE knew about the purchase.

Axon Valuation, Momentum and Yield

A P/E ratio of 234.06 on trailing earnings puts Axon in territory where the market is pricing in years of compounding growth, not current profitability. That premium isn't new: the company just closed its ninth consecutive quarter of revenue growth above 30%, and federal work, including a 370 million dollar Department of Homeland Security body camera and software contract signed in 2023, remains largely unspent, with only about 67.5 million dollars drawn so far according to HigherGov data. President Josh Isner told investors at the William Blair Growth Stock Conference on June 4 that selling new products into the existing customer base, particularly federal law enforcement, is a more attractive market than defense contracting. An RSI of 69.38 sits just under the conventional overbought threshold of 70, consistent with a stock that ran up more than 20% over two trading sessions after the CNBC report before Tuesday's pullback. Axon pays no dividend, so total return here rests entirely on multiple expansion and earnings growth rather than yield. The 52 week range of 366.00 to 665.07 dollars shows a stock that has nearly doubled from its low, with the current 601.53 dollar price sitting well above the midpoint despite the day's drop. Market cap stands at 51.62 billion dollars.

The bull case rests on federal demand: a potential ICE order that would more than quadruple the agency's current supply of roughly 4,300 devices, an unspent DHS contract with room to run, and a near monopoly position in tasers that gives Axon pricing power as enforcement budgets expand. The bear case centers on valuation risk layered onto political risk. A P/E above 230 leaves little room for error if federal contract timelines slip or public scrutiny over the administration's holdings complicates procurement optics. An RSI near 70 suggests the recent rally has already priced in a favorable outcome on the ICE contract before it has even been awarded.

What the ICE Contract Decision Means for Axon Shares

The 220 million dollar taser order remains unawarded, and that unresolved status is precisely why the stock swung so sharply this week. Ethics scrutiny alone does not change Axon's fundamentals, but it does introduce headline risk around a company whose federal pipeline, from the DHS body camera deal to the pending ICE request, is central to sustaining growth rates that have justified its premium multiple.